We look forward to a lively and informative discussion with you on cutting-edge developments in health care and life sciences. Our bloggers come from our interdisciplinary practice groups and have experience and insights about navigating the fast-paced, heavily regulatory environment that
surrounds scientific research, life-sciences product development, intellectual property protection, product marketing and sales and the intersection with the health care industry. Business and financing pressures, regulatory scrutiny, and litigation threats facing research institutions, scientists, venture capitalists
investment banks, pharmaceutical manufacturers, bio informatic companies, biotech and medical device entities and health care providers will be topics that we’ll look forward to discussing with you.
New ethical questions have been spurred by the recent lung transplantation case involving a 10-year old girl from Pennsylvania. Sarah Murnaghan, who was diagnosed...
As pharmaceutical and device manufacturers and others are scrambling to finalize interpretations and implementation of the U.S. Physician Payment Sunshine Act, the French government...
Krista Cosner published, “Overlapping Post-Marketing Challenges for Biopharmaceuticals: Pharmacovigilance, Products Liability, and Biosimilars,” in the following publications: Bloomberg Services (May 16), BioTech Watch (May...